A detailed history of Arrowstreet Capital, Limited Partnership transactions in Abb Vie Inc. stock. As of the latest transaction made, Arrowstreet Capital, Limited Partnership holds 459,149 shares of ABBV stock, worth $82.6 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
459,149
Previous 183,074 150.8%
Holding current value
$82.6 Million
Previous $31.4 Million 188.76%
% of portfolio
0.08%
Previous 0.03%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$163.84 - $199.33 $45.2 Million - $55 Million
276,075 Added 150.8%
459,149 $90.7 Million
Q2 2024

Aug 14, 2024

BUY
$154.79 - $180.76 $15.1 Million - $17.6 Million
97,394 Added 113.67%
183,074 $31.4 Million
Q1 2024

May 15, 2024

SELL
$159.82 - $182.1 $42.1 Million - $48 Million
-263,428 Reduced 75.46%
85,680 $15.6 Million
Q4 2023

Feb 14, 2024

BUY
$137.6 - $154.97 $38.2 Million - $43 Million
277,358 Added 386.56%
349,108 $54.1 Million
Q3 2023

Nov 14, 2023

BUY
$133.59 - $154.65 $616,117 - $713,245
4,612 Added 6.87%
71,750 $10.7 Million
Q2 2023

Aug 14, 2023

BUY
$132.51 - $164.9 $6.78 Million - $8.44 Million
51,202 Added 321.3%
67,138 $9.05 Million
Q1 2023

May 15, 2023

BUY
$144.61 - $166.54 $2.3 Million - $2.65 Million
15,936 New
15,936 $2.54 Million
Q3 2022

Nov 14, 2022

SELL
$134.21 - $153.93 $142 Million - $162 Million
-1,055,102 Reduced 24.7%
3,215,907 $432 Million
Q2 2022

Aug 15, 2022

SELL
$137.62 - $174.96 $52.4 Million - $66.7 Million
-381,113 Reduced 8.19%
4,271,009 $654 Million
Q1 2022

May 13, 2022

BUY
$131.98 - $163.75 $497 Million - $617 Million
3,768,579 Added 426.53%
4,652,122 $754 Million
Q4 2021

Feb 14, 2022

SELL
$107.43 - $135.93 $111 Million - $140 Million
-1,029,449 Reduced 53.81%
883,543 $120 Million
Q3 2021

Nov 12, 2021

BUY
$106.4 - $120.78 $192 Million - $218 Million
1,804,393 Added 1661.52%
1,912,992 $206 Million
Q2 2021

Aug 13, 2021

SELL
$105.21 - $117.21 $2.26 Million - $2.52 Million
-21,501 Reduced 16.53%
108,599 $12.2 Million
Q1 2021

May 14, 2021

BUY
$102.3 - $112.62 $13.3 Million - $14.7 Million
130,100 New
130,100 $14.1 Million
Q4 2020

Feb 12, 2021

SELL
$80.49 - $108.67 $20.4 Million - $27.5 Million
-253,000 Closed
0 $0
Q3 2020

Nov 12, 2020

BUY
$85.91 - $100.83 $18.9 Million - $22.2 Million
220,000 Added 666.67%
253,000 $22.2 Million
Q2 2020

Aug 12, 2020

SELL
$73.37 - $98.18 $420 Million - $562 Million
-5,722,097 Reduced 99.43%
33,000 $3.24 Million
Q1 2020

May 15, 2020

BUY
$64.5 - $97.79 $40.4 Million - $61.3 Million
626,639 Added 12.22%
5,755,097 $438 Million
Q4 2019

Feb 13, 2020

SELL
$72.13 - $90.25 $168 Million - $211 Million
-2,335,648 Reduced 31.29%
5,128,458 $454 Million
Q3 2019

Nov 14, 2019

BUY
$62.98 - $75.72 $4.1 Million - $4.93 Million
65,172 Added 0.88%
7,464,106 $565 Million
Q2 2019

Aug 14, 2019

BUY
$65.7 - $83.98 $31.7 Million - $40.6 Million
483,145 Added 6.99%
7,398,934 $538 Million
Q1 2019

May 15, 2019

SELL
$77.14 - $90.79 $17.6 Million - $20.7 Million
-228,540 Reduced 3.2%
6,915,789 $557 Million
Q4 2018

Feb 14, 2019

SELL
$77.85 - $96.01 $149 Million - $184 Million
-1,918,859 Reduced 21.17%
7,144,329 $659 Million
Q3 2018

Nov 14, 2018

SELL
$88.91 - $98.84 $259 Million - $288 Million
-2,917,106 Reduced 24.35%
9,063,188 $857 Million
Q2 2018

Aug 14, 2018

BUY
$89.78 - $106.23 $338 Million - $400 Million
3,763,730 Added 45.81%
11,980,294 $1.11 Billion
Q1 2018

May 14, 2018

BUY
$92.01 - $123.21 $564 Million - $756 Million
6,133,793 Added 294.5%
8,216,564 $778 Million
Q4 2017

Feb 09, 2018

SELL
$89.56 - $98.21 $70.4 Million - $77.2 Million
-786,282 Reduced 27.41%
2,082,771 $201 Million
Q3 2017

Nov 14, 2017

BUY
$69.85 - $89.22 $200 Million - $256 Million
2,869,053
2,869,053 $255 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Arrowstreet Capital, Limited Partnership Portfolio

Follow Arrowstreet Capital, Limited Partnership and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

News

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.